Use of Dual-Layered Stents in Endovascular Treatment of Extracranial Stenosis of the Internal Carotid Artery

• Published in: JACC. Cardiovascular interventions Vol. 11; no. 23; pp. 2405 - 2411
• Main Authors: Stabile, Eugenio, de Donato, Gianmarco, Musialek, Piotr, De Loose, Koen, Nerla, Roberto, Sirignano, Pasqualino, Chianese, Salvatore, Mazurek, Adam, Tesorio, Tullio, Bosiers, Marc, Setacci, Carlo, Speziale, Francesco, Micari, Antonio, Esposito, Giovanni
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01.12.2018
• Subjects: carotid artery disease; carotid artery stenting; stroke; NIHSS; carotid artery stenting; CAS; DLS; EPDs; carotid artery disease; stroke
• ISSN: 1936-8798; 1876-7605
• DOI: 10.1016/j.jcin.2018.06.047

The aim of this study was to evaluate the clinical efficacy of dual-layered mesh-covered carotid stent systems (DLS) for carotid artery stenting (CAS). The need to minimize the risk for plaque debris prolapsing between stent struts following CAS has resulted in the development of DLS. Small clinical studies evaluating 2 available devices, Roadsaver and CGuard, have been recently published; none of these studies is sufficiently powered to test the role of common risk factors on the occurrence of stroke at 30 days post-CAS. A search was performed of multiple electronic databases for studies larger than 100 cases of CAS with DLS. Four single-arm prospective studies were identified, and individual patient data were collected. The primary endpoint was the occurrence of stroke at 30 days; secondary endpoints were technical and procedural success, periprocedural stroke, and in-hospital and 30-day rates of death. The Roadsaver and CGuard stents were used in similar proportions, and technical success was achieved in all procedures (100% [n = 556]). There were 6 periprocedural strokes (1.08%; all minor). During 30-day follow-up, there was 1 death (0.17%) from myocardial infarction and 1 additional minor stroke (0.17%). The cumulative 30-day mortality rate was 0.17%, and the incidence of stroke at 30 days was 1.25%. No predictors of stroke at 30 days could be identified. This meta-analysis suggests that DLS can be safely used for CAS, and their use minimizes the incremental risk related to symptomatic status and other risk factors. [Display omitted]